Brian Newman - 31 Mar 2026 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: CVS
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 16:57:02 UTC
Prior SEC filing: 06 Jan 2026
Next SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Brian Newman

Key filing fact

Brian Newman filed Form 4 for CVS HEALTH Corp (CVS) on 02 Apr 2026.

Key facts

This page summarizes Brian Newman's Form 4 filing for CVS HEALTH Corp (CVS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2026, 16:57.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001788049 Primary reporting owner

Newman Brian

Relationship: EVP, Chief Financial Officer
Address: ONE CVS DRIVE, WOONSOCKET
Signature: /s/ Brian Newman
Signature date: 02 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CVS transaction

Common Stock (RSUs)

Award

Transaction value
Shares: +19,493
Change %: +89%
Price: $71.82^*
Shares after: 41,354
Date: 31 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CVS transaction Derivative

Stock Option

Award

Transaction value
Shares: +125,748
Change %
Price: $71.82^*
Shares after: 125,748
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,748
Exercise price: $71.82
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027.

Footnote F2

Option becomes exercisable in three equal annual installments, commencing 3/31/2027.